Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2-Reference-Cited by-同舟云学术

Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2

Published:2012-09-10 Issue:7420 Volume:490 Page:417-420
ISSN:0028-0836
Container-title:Nature
language:en
Short-container-title:Nature

Author:

Rolland Morgane,Edlefsen Paul T.,Larsen Brendan B.,Tovanabutra Sodsai,Sanders-Buell Eric,Hertz Tomer,deCamp Allan C.,Carrico Chris,Menis Sergey,Magaret Craig A.,Ahmed Hasan,Juraska Michal,Chen Lennie,Konopa Philip,Nariya Snehal,Stoddard Julia N.,Wong Kim,Zhao Hong,Deng Wenjie,Maust Brandon S.,Bose Meera,Howell Shana,Bates Adam,Lazzaro Michelle,O’Sullivan Annemarie,Lei Esther,Bradfield Andrea,Ibitamuno Grace,Assawadarachai Vatcharain,O’Connell Robert J.,deSouza Mark S.,Nitayaphan Sorachai,Rerks-Ngarm Supachai,Robb Merlin L.,McLellan Jason S.,Georgiev Ivelin,Kwong Peter D.,Carlson Jonathan M.,Michael Nelson L.,Schief William R.,Gilbert Peter B.,Mullins James I.,Kim Jerome H.

Publisher

Springer Science and Business Media LLC

Subject

Multidisciplinary

Link

http://www.nature.com/articles/nature11519.pdf

Reference30 articles.

1. Rerks-Ngarm, S. et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N. Engl. J. Med. 361, 2209–2220 (2009)

2. Haynes, B. F. et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N. Engl. J. Med. 366, 1275–1286 (2012)

3. Plotkin, S. A. & Gilbert, P. B. Nomenclature for immune correlates of protection after vaccination. Clin. Infect. Dis. 54, 1615–1617 (2012)

4. Rolland, M. & Gilbert, P. Evaluating immune correlates in HIV type 1 vaccine efficacy trials: what RV144 may provide. AIDS Res. Hum. Retroviruses 28, 400–404 (2012)

5. Gilbert, P. B., Self, S. G. & Ashby, M. A. Statistical methods for assessing differential vaccine protection against human immunodeficiency virus types. Biometrics 54, 799–814 (1998)

Cited by 376 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Polytopic fractional delivery of an HIV vaccine alters cellular responses and results in increased epitope breadth in a phase 1 randomized trial;eBioMedicine;2024-02

2. Potent antibody-dependent cellular cytotoxicity of a V2-specific antibody is not sufficient for protection of macaques against SIV challenge;PLOS Pathogens;2024-01-22

3. The V2 domain of HIV gp120 mimics an interaction between CD4 and integrin ⍺4β7;PLOS Pathogens;2023-12-08

4. Potent antibody-dependent cellular cytotoxicity of a V2-specific antibody is not sufficient for protection of macaques against SIV challenge;2023-11-15

5. Mosaic HIV-1 vaccination induces anti-viral CD8 ⁺ T cell functionality in the phase 1/2a clinical trial APPROACH;Journal of Virology;2023-10-31